Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Therapeuticsmd Inc (TXMD)

Therapeuticsmd Inc (TXMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
TherapeuticsMD: Q1 Earnings Snapshot

TherapeuticsMD: Q1 Earnings Snapshot

TXMD : 2.05 (-1.44%)
TherapeuticsMD: Q3 Earnings Snapshot

TherapeuticsMD: Q3 Earnings Snapshot

TXMD : 2.05 (-1.44%)
TherapeuticsMD: Q2 Earnings Snapshot

TherapeuticsMD: Q2 Earnings Snapshot

TXMD : 2.05 (-1.44%)
TherapeuticsMD: Q1 Earnings Snapshot

TherapeuticsMD: Q1 Earnings Snapshot

TXMD : 2.05 (-1.44%)
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy

TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TXMD : 2.05 (-1.44%)
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December...

TXMD : 2.05 (-1.44%)
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced...

TXMD : 2.05 (-1.44%)
Pre-Market Brief: Stocks Mixed As Labor Market Strength Weigh On Sentiment

December S&P 500 futures (ESZ22) are trending down -0.30% this morning after three major US benchmark indices closed mixed on Friday as the November payrolls report fueled expectations the Federal Reserve...

ESZ22 : 3,871.47s (-0.66%)
TXMD : 2.05 (-1.44%)
IOVA : 8.53 (-1.04%)
IMPP : 3.74 (-2.86%)
CLVS : 0.0812 (-5.58%)
UTHR : 281.86 (+2.21%)
SBUX : 79.38 (-0.64%)
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements...

TXMD : 2.05 (-1.44%)
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TXMD : 2.05 (-1.44%)
IDXG : 1.3700 (-0.25%)

Barchart Exclusives

3 Small-Cap Stocks Set To Skyrocket
These under-the-radar companies may offer greater long-term rewards. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar